At the time of writing, Ovid Therapeutics Inc [OVID] stock is trading at $0.61, up 10.07%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The OVID shares have gain 52.53% over the last week, with a monthly amount glided 104.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ovid Therapeutics Inc [NASDAQ: OVID] stock has seen the most recent analyst activity on June 18, 2024, when Oppenheimer downgraded its rating to a Perform. Previously, B. Riley Securities started tracking the stock with Buy rating on April 30, 2024, and set its price target to $9. On April 29, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $9 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $8 on April 05, 2024. BTIG Research initiated its recommendation with a Buy and recommended $11 as its price target on December 21, 2023. Oppenheimer started tracking with a Outperform rating for this stock on October 13, 2023, and assigned it a price target of $8. In a note dated April 20, 2021, Cantor Fitzgerald downgraded an Neutral rating on this stock but restated the target price of $4.
For the past year, the stock price of Ovid Therapeutics Inc fluctuated between $0.24 and $1.47. Currently, Wall Street analysts expect the stock to reach $7.33 within the next 12 months. Ovid Therapeutics Inc [NASDAQ: OVID] shares were valued at $0.61 at the most recent close of the market. An investor can expect a potential return of 1101.64% based on the average OVID price forecast.
Analyzing the OVID fundamentals
According to Ovid Therapeutics Inc [NASDAQ:OVID], the company’s sales were 0.55M for trailing twelve months, which represents an -12.16% plunge. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -104.04%, Pretax Profit Margin comes in at -45.57%, and Net Profit Margin reading is -45.57%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.34 and Total Capital is -0.79. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.24.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Ovid Therapeutics Inc [NASDAQ:OVID] has a current ratio of 4.93. In addition, the Quick Ratio stands at 4.93 and the Cash Ratio stands at 2.27. Considering the valuation of this stock, the price to sales ratio is 78.27, the price to book ratio is 0.73.
Transactions by insiders
Recent insider trading involved ALEXANDER MARGARET A., President and COO, that happened on Feb 26 ’25 when 5279.0 shares were sold. CBFO, Rona Jeffrey A completed a deal on Feb 26 ’25 to sell 3902.0 shares. Meanwhile, President and COO ALEXANDER MARGARET A. bought 6810.0 shares on Jan 27 ’25.
